Comment: Impact of Linezolid on Economic Outcomes and Determinants of Cost in a Clinical Trial Evaluating Patients with MRSA Complicated Skin and Soft-Tissue Infections

McKinnon PS , Sorensen SV , Liu LZ , Itani KMF . Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006;40:1017-23. Epub 23 May 2006. DOI 10.1345/aph.1G728

Weigelt J , Itani K , Stevens D , Lau W , Dryden M , Knirsch C , and the Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.

Kalil AC , Puumala S , Stoner J. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? Antimicrob Agents Chemother 2006;50:1910-1.